食品伙伴網(wǎng)訊  據(jù)歐盟食品安全局（EFSA）消息，繼歐洲爆發(fā)馬肉風波后，歐盟委員會要求歐盟食品安全局就馬肉中的抗炎藥苯基丁氮酮（保泰松）對人體的風險進行評估。

    在部分歐盟成員國，保泰松可作為緩解疼痛以及抗炎的藥物用于狗、馬等非產(chǎn)肉動物。歐盟嚴禁保泰松用于產(chǎn)肉動物，因此任何動物性食品檢出該藥物都是非法使用的結(jié)果。

    部分原文報道如下：

    The European Union agencies will provide scientific advice by 15 April 2013 to help inform decision-making of the European Commission with regard to these recent findings.

    In carrying out the joint risk assessment, the two agencies will use all available scientific evidence and consider data and results of ongoing testing of horsemeat in Member States as these become available.

    In a joint statement, EFSA and EMA will provide advice on any potential risk for consumers arising from the presence of phenylbutazone residues in horsemeat. In this regard, the agencies will consider both the risk posed from consumption of horsemeat itself as well as that arising from other products illegally contaminated with horsemeat. The agencies have been asked to advise, where appropriate, if additional control options are needed to minimise any risks identified.

    Phenylbutazone is used sparingly in human medicine for the treatment of severe inflammatory conditions where no other treatment is considered suitable. In veterinary medicine its use is permitted in some Member States for pain relief and to reduce inflammation in non-food producing animals （dogs, sport horses）。

    原文鏈接：<http://www.efsa.europa.eu/en/press/news/130307.htm>